Detailed Information on Publication Record
2023
Association of statin pre-treatment with baseline stroke severity and outcome in patients with acute ischemic stroke and received reperfusion treatment: An observational study
ESCUDERO-MARTINEZ, Irene, Marius MATUSEVICIUS, Ana PAVIA-NUNES, Petr SEVCIK, Miroslava NEVSIMALOVA et. al.Basic information
Original name
Association of statin pre-treatment with baseline stroke severity and outcome in patients with acute ischemic stroke and received reperfusion treatment: An observational study
Authors
ESCUDERO-MARTINEZ, Irene (guarantor), Marius MATUSEVICIUS, Ana PAVIA-NUNES, Petr SEVCIK (203 Czech Republic), Miroslava NEVSIMALOVA (203 Czech Republic), Viiu-Marika RAND, Janika KORV, Manuel CAPPELLARI, Robert MIKULÍK (203 Czech Republic, belonging to the institution), Danilo TONI and Niaz AHMED
Edition
International Journal of Stroke, London, SAGE, 2023, 1747-4930
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30210 Clinical neurology
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 6.700 in 2022
RIV identification code
RIV/00216224:14110/23:00129975
Organization unit
Faculty of Medicine
UT WoS
000798307100001
Keywords in English
Stroke; statins; prevention; neuroprotection; severity; lipids
Tags
International impact, Reviewed
Změněno: 26/1/2024 09:58, Mgr. Tereza Miškechová
Abstract
V originále
Background: Statins have an important role in stroke prevention, especially in high-risk populations and may also affect the initial stroke severity and outcomes in patients taking them before an ischemic stroke. Aims: Our aim was to evaluate the association of statin pre-treatment with the severity in acute ischemic stroke (AIS). Methods: We analyzed AIS patients received intravenous thrombolysis (IVT) and/or endovascular thrombectomy (EVT) and recorded in the SITS International Thrombolysis and Thrombectomy Registry from 2011 to 2017. We identified patients with statin information at baseline. The primary outcome was baseline National Institutes of Health Stroke Scale (NIHSS) score. Secondary outcomes were NIHSS score at 24 h, symptomatic intracerebral hemorrhage (SICH) and functional outcome at 90 days after acute intervention. Multivariable linear and logistic regression and propensity score matching (PSM) was used to quantify the effect of statin pre-treatment. Results: Of 93,849 patients, 23,651 (25.2%) were treated with statins prior the AIS. Statin pre-treatment group was older and had higher comorbidity. Median NIHSS at baseline was similar between groups. In the adjusted and PSM analysis, statin pre-treatment was inversely associated with baseline NIHSS (odds ratio (OR) = 0.77, 95% confidence interval (CI) = 0.6-0.99 and OR for PSM 0.73, 95% CI = 0.54-0.99, p = 0.004) and independently associated with mild stroke defined as NIHSS <= 8 in adjusted and PSM analysis (OR = 1.21, 95% CI = 1.1-1.34, p < 0.001 and OR for PSM 1.17, 95% CI = 1.05-1.31, p = 0.007). Regarding secondary outcomes, there were no differences in functional outcomes, death nor SICH rates between groups. Conclusion: Prior treatment with statins was associated with lower NIHSS at baseline. However, this association did not translate into any difference regarding functional outcome at 90 days. No association was found regarding SICH. These findings indicate the need of further studies to assess the effect on statin pre-treatment on initial stroke severity.